IP Library › Granted Patent US 12,202,799
Granted Patent B2
US 12,202,799 · App. 17/512,978 · Granted Jan 21, 2025

Agents for differentiating stem cells and treating cancer

Inventors: Cynthia Bamdad (Waltham, MA); Scott Moe (Waltham, MA)
Assignee: MINERVA BIOTECHNOLOGIES CORPORATION
C07D211/16A61P35/00C07D213/74C07D295/185C07D401/04C07D401/06C07D471/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,202,799
App. No.
17/512,978
Granted
Jan 21, 2025
Kind
B2
Abstract

The present application discloses a method for identifying an agent for the treatment or prevention of cancer or metastatic cancer comprising the steps of contacting stem cell with a potential agent, and identifying an agent that induces differentiation, or inhibits stem cell pluripotency or growth of the stem cell, wherein such agent is determined to be an anti-cancer agent.

Claims (73)

1. A compound, or pharmaceutically acceptable salt thereof, according to:

(a) Formula 15:

wherein,

R 1 is H, optionally substituted C1-C6 alkyl; optionally substituted C2-C6 alkenyl; optionally substituted C1-C6 alkoxy; optionally substituted C6-C12 aryl; optionally substituted C1-C9 heteroaryl with 1 to 4 ring atoms independently selected from N, S, and O; optionally substituted C7-C15 arylalkyl; optionally substituted C2-C15 heteroarylalkyl with 1 to 4 ring atoms independently selected from N, S, and O; optionally substituted C7-C15 arylalkenyl; optionally substituted C3-C8 cycloalkyl; or an optionally substituted C4-C8 cycloalkylalkyl;

R 2 is hydrogen, optionally substituted C1-C6 alkoxy, trifluoromethyl, halogen, methylcarboxy, ethylcarboxy, optionally substituted C1-C6 alkyl, —OH, —SH, —NH 2 , —N 3 , —CN, —NO 2 , —CHO, —COOH, —CONH 2 , —C(═NH)NH 2 , or —SO 3 H;

R 5 is H, optionally substituted C1-C6 alkyl, optionally substituted C 7 -C 15 arylalkyl, or 2-phenylethyl;

Z 2 is a bond, —NH—, —O—, —S—, —CH(CH 3 )—, —(CH 2 ) n —, —CH═CH—, —CO—, —SO—, —SO 2 —, —C(═NH)—, —CH 2 NH(CO)—, —CH 2 NH(CO)O—, —CH 2 NH(CO)NH—; —(CH 2 ) n NH(CO)—, —(CH 2 ) n NH(CO)O—, —(CH 2 ) m NH(CO)NH—; and

R 4 is H, optionally substituted C1-C9 alkyl; optionally substituted C2-C6 alkenyl; optionally substituted C6-C12 aryl; optionally substituted C1-C9 heteroaryl with 1 to 4 ring atoms independently selected from N, S, and O; optionally substituted C7-C15 arylalkyl; —O-tert-butyl;

wherein m=1-5; n=1-8;

where “substituted” means substituted with one or more substituents independently selected from halogen, trifluoromethyl, methylcarboxy, ethylcarboxy, C1-C6 alkoxy, C1-C6 alkyl, —OH, —SH, —NH 2 , —N 3 , —CN, —NO 2 , —CHO, —COOH, —CONH 2 , —C(═NH)NH 2 , and —SO 3 H; or

(b) Formula 16:

wherein,

G 3 is CH or N;

R 1 is H, optionally substituted C1-C6 alkyl; optionally substituted C2-C6 alkenyl; optionally substituted C1-C6 alkoxy; optionally substituted C6-C12 aryl; optionally substituted C1-C9 heteroaryl with 1 to 4 ring atoms independently selected from N, S, and O; optionally substituted C7-C15 arylalkyl; optionally substituted C2-C15 heteroarylalkyl with 1 to 4 ring atoms independently selected from N, S, and O; optionally substituted C7-C15 arylalkenyl; optionally substituted C3-C8 cycloalkyl; or an optionally substituted C4-C8 cycloalkylalkyl;

R 2 is hydrogen, optionally substituted C1-C6 alkoxy, trifluoromethyl, halogen, methylcarboxy, ethylcarboxy, optionally substituted C1-C6 alkyl, —OH, —SH, —NH 2 , —N 3 , —CN, —NO 2 , —CHO, —COOH, —CONH 2 , —C(═NH)NH 2 , or —SO 3 H;

R 5 is optionally substituted C1-C6 alkyl, optionally substituted C 7 -C 15 arylalkyl, or 2-phenylethyl;

Z 2 is a bond, —NH—, —O—, —S—, —CH(CH 3 )—, —(CH 2 ) n —, —CH═CH—, —CO—, —SO—, —SO 2 —, —C(═NH)—, —CH 2 NH(CO)—, —CH 2 NH(CO)O—, —CH 2 NH(CO)NH—; —(CH 2 ) n NH(CO)—, —(CH 2 ) n NH(CO)O—, —(CH 2 ) m NH(CO)NH—; and

R 4 is H, optionally substituted C1-C9 alkyl; optionally substituted C2-C6 alkenyl; optionally substituted C6-C12 aryl; optionally substituted C1-C9 heteroaryl with 1 to 4 ring atoms independently selected from N, S, and O; optionally substituted C7-C15 arylalkyl; or —O-tert-butyl;

wherein m=1-5; n=1-8;

where “substituted” means substituted with one or more substituents independently selected from halogen, trifluoromethyl, methylcarboxy, ethylcarboxy, C1-C6 alkoxy, C1-C6 alkyl, —OH, —SH, —NH 2 , —N 3 , —CN, —NO 2 , —CHO, —COOH, —CONH 2 , —C(═NH)NH 2 , and —SO 3 H; or

(c) Formula 17:

wherein,

R 1 is H, optionally substituted C1-C6 alkyl; optionally substituted C2-C6 alkenyl; optionally substituted C1-C6 alkoxy; optionally substituted C6-C12 aryl; optionally substituted C1-C9 heteroaryl with 1 to 4 ring atoms independently selected from N, S, and O; optionally substituted C7-C15 arylalkyl; optionally substituted C2-C15 heteroarylalkyl with 1 to 4 ring atoms independently selected from N, S, and O; optionally substituted C7-C15 arylalkenyl; optionally substituted C3-C8 cycloalkyl; or an optionally substituted C4-C8 cycloalkylalkyl;

R 2 is hydrogen, optionally substituted C1-C6 alkoxy, trifluoromethyl, halogen, methylcarboxy, ethylcarboxy, optionally substituted C1-C6 alkyl, —OH, —SH, —NH 2 , —N 3 , —CN, —NO 2 , —CHO, —COOH, —CONH 2 , —C(═NH)NH 2 , or —SO 3 H;

R 5 is H, optionally substituted C1-C6 alkyl, optionally substituted C 7 -C 15 arylalkyl, or 2-phenylethyl;

Z 2 is a bond, —NH—, —O—, —S—, —CH(CH 3 )—, —(CH 2 ) n —, —CH═CH—, —CO—, —SO—, —SO 2 —, —C(═NH)—, —CH 2 NH(CO)—, —CH 2 NH(CO)O—, —CH 2 NH(CO)NH—; —(CH 2 ) n NH(CO)—, —(CH 2 ) n NH(CO)O—, —(CH 2 ) m NH(CO)NH—; and

R 4 is H, optionally substituted C1-C9 alkyl; optionally substituted C2-C6 alkenyl; optionally substituted C6-C12 aryl; optionally substituted C1-C9 heteroaryl with 1 to 4 ring atoms independently selected from N, S, and O; optionally substituted C7-C15 arylalkyl; or —O-tert-butyl;

where m=1-5; n=1-8;

where “substituted” means substituted with one or more substituents independently selected from halogen, trifluoromethyl, methylcarboxy, ethylcarboxy, C1-C6 alkoxy, C1-C6 alkyl, —OH, —SH, —NH 2 , —N 3 , —CN, —NO 2 , —CHO, —COOH, —CONH 2 , —C(═NH)NH 2 , and —SO 3 H;

or a pharmaceutically acceptable salt thereof.

2. The compound or pharmaceutically acceptable salt thereof, according to claim 1 , wherein the compound is a compound of Formula 15:

wherein,

R 1 is H, optionally substituted C1-C6 alkyl; optionally substituted C2-C6 alkenyl; optionally substituted C1-C6 alkoxy; optionally substituted C6-C12 aryl; optionally substituted C1-C9 heteroaryl with 1 to 4 ring atoms independently selected from N, S, and O; optionally substituted C7-C15 arylalkyl; optionally substituted C2-C15 heteroarylalkyl with 1 to 4 ring atoms independently selected from N, S, and O; optionally substituted C7-C15 arylalkenyl; optionally substituted C3-C8 cycloalkyl; or an optionally substituted C4-C8 cycloalkylalkyl;

R 2 is hydrogen, optionally substituted C1-C6 alkoxy, trifluoromethyl, halogen, methylcarboxy, ethylcarboxy, optionally substituted C1-C6 alkyl, —OH, —SH, —NH 2 , —N 3 , —CN, —NO 2 , —CHO, —COOH, —CONH 2 , —C(═NH)NH 2 , or —SO 3 H;

R 5 is H, optionally substituted C1-C6 alkyl, optionally substituted C 7 -C 15 arylalkyl, or 2-phenylethyl;

Z 2 is a bond, —NH—, —O—, —S—, —CH(CH 3 )—, —(CH 2 ) n —, —CH═CH—, —CO—, —SO—, —SO 2 —, —C(═NH)—, —CH 2 NH(CO)—, —CH 2 NH(CO)O—, —CH 2 NH(CO)NH—; —(CH 2 ) n NH(CO)—, —(CH 2 ) n NH(CO)O—, —(CH 2 ) m NH(CO)NH—; and

R 4 is H, optionally substituted C1-C9 alkyl; optionally substituted C2-C6 alkenyl; optionally substituted C6-C12 aryl 1; optionally substituted C1-C9 heteroaryl with 1 to 4 ring atoms independently selected from N, S, and O; optionally substituted C7-C15 arylalkyl; —O-tert-butyl;

wherein m=1-5; n=1-8;

where “substituted” means substituted with one or more substituents independently selected from halogen, trifluoromethyl, methylcarboxy, ethylcarboxy, C1-C6 alkoxy, C1-C6 alkyl, —OH, —SH, —NH 2 , —N 3 , —CN, —NO 2 , —CHO, —COOH, —CONH 2 , —C(═NH)NH 2 , and —SO 3 H.

3. The compound or pharmaceutically acceptable salt thereof, according to claim 1 , wherein the compound is a compound of Formula 16:

wherein,

G 3 is CH or N;

R 1 is H, optionally substituted C1-C6 alkyl; optionally substituted C2-C6 alkenyl; optionally substituted C1-C6 alkoxy; optionally substituted C6-C12 aryl; optionally substituted C1-C9 heteroaryl with 1 to 4 ring atoms independently selected from N, S, and O; optionally substituted C7-C15 arylalkyl; optionally substituted C2-C15 heteroarylalkyl with 1 to 4 ring atoms independently selected from N, S, and O; optionally substituted C7-C15 arylalkenyl; optionally substituted C3-C8 cycloalkyl; or an optionally substituted C4-C8 cycloalkylalkyl;

R 2 is hydrogen, optionally substituted C1-C6 alkoxy, trifluoromethyl, halogen, methylcarboxy, ethylcarboxy, optionally substituted C1-C6 alkyl, —OH, —SH, —NH 2 , —N 3 , —CN, —NO 2 , —CHO, —COOH, —CONH 2 , —C(═NH)NH 2 , or —SO 3 H;

R 5 is optionally substituted C1-C6 alkyl, optionally substituted C 7 -C 15 arylalkyl, or 2-phenylethyl;

Z 2 is a bond, —NH—, —O—, —S—, —CH(CH 3 )—, —(CH 2 ) n —, —CH═CH—, —CO—, —SO—, —SO 2 —, —C(═NH)—, —CH 2 NH(CO)—, —CH 2 NH(CO)O—, —CH 2 NH(CO)NH—, —(CH 2 ) n NH(CO)—, —(CH 2 ) n NH(CO)O—, —(CH 2 ) m NH(CO)NH—; and

R 4 is H, optionally substituted C1-C9 alkyl; optionally substituted C2-C6 alkenyl; optionally substituted C6-C12 aryl; optionally substituted C1-C9 heteroaryl with 1 to 4 ring atoms independently selected from N, S, and O; optionally substituted C7-C15 arylalkyl; or —O-tert-butyl;

wherein m=1-5; n=1-8;

where “substituted” means substituted with one or more substitutents independently selected from halogen, trifluoromethyl, methylcarboxy, ethylcarboxy, C1-C6 alkoxy, C1-C6 alkyl, —OH, —SH, —NH 2 , —N 3 , —CN, —NO 2 , —CHO, —COOH, —CONH 2 , —C(═NH)NH 2 , and —SO 3 H.

4. The compound or pharmaceutically acceptable salt thereof, according to claim 1 , wherein the compound is a compound of Formula 17:

wherein,

R 1 is H, optionally substituted C1-C6 alkyl; optionally substituted C2-C6 alkenyl; optionally substituted C1-C6 alkoxy; optionally substituted C6-C12 aryl; optionally substituted C1-C9 heteroaryl with 1 to 4 ring atoms independently selected from N, S, and O; optionally substituted C7-C15 arylalkyl; optionally substituted C2-C15 heteroarylalkyl with 1 to 4 ring atoms independently selected from N, S, and O; optionally substituted C7-C15 arylalkenyl; optionally substituted C3-C8 cycloalkyl; or an optionally substituted C4-C8 cycloalkylalkyl;

R 2 is hydrogen, optionally substituted C1-C6 alkoxy, trifluoromethyl, halogen, methylcarboxy, ethylcarboxy, optionally substituted C1-C6 alkyl, —OH, —SH, —NH 2 , —N 3 , —CN, —NO 2 , —CHO, —COOH, —CONH 2 , —C(═NH)NH2, or —SO 3 H;

R 5 is H, optionally substituted C1-C6 alkyl, optionally substituted C 7 -C 15 arylalkyl, or 2-phenylethyl;

Z 2 is a bond, —NH—, —O—, —S—, —CH(CH 3 )—, —(CH 2 ) n —, —CH—CH—, —CO—, —SO—, —SO 2 —, —C(═NH)—, —CH 2 NH(CO)—, —CH 2 NH(CO)O—, —CH 2 NH(CO)NH—; —(CH 2 ) n NH(CO)—, —(CH 2 ) n NH(CO)O—, —(CH 2 ) m NH(CO)NH—; and

R 4 is H, optionally substituted C1-C9 alkyl; optionally substituted C2-C6 alkenyl; optionally substituted C6-C12 aryl; optionally substituted C1-C9 heteroaryl with 1 to 4 ring atoms independently selected from N, S, and O; optionally substituted C7-C15 arylalkyl; or —O-tert-butyl;

wherein m=1-5, n=1-8;

where “substituted” means substituted with one or more substitutents independently selected from halogen, trifluoromethyl, methylcarboxy, ethylcarboxy, C1-C6 alkoxy, C1-C6 alkyl, —OH, —SH, —NH 2 , —N 3 , —CN, —NO 2 , —CHO, —COOH, —CONH 2 , —C(═NH)NH 2 , and —SO 3 H.

5. The compound or pharmaceutically acceptable salt thereof, according to claim 1 , wherein the compound is a compound of Formula 15, Formula 16, or Formula 17, and wherein R 1 is H.

6. The compound or pharmaceutically acceptable salt thereof, according to claim 1 , wherein the compound is a compound of Formula 15, Formula 16, or Formula 17, wherein Z 2 is —O—, —NH—, or —CH 2 —.

7. The compound or pharmaceutically acceptable salt thereof, according to claim 1 , wherein the compound is a compound of Formula 15, Formula 16, or Formula 17, wherein R 5 is methyl, Z 2 is —O—, —NH—, or —CH 2 —, R 4 is t-butyl, and R 2 is hydrogen, halogen, trifluoromethyl, methylcarboxy, ethylcarboxy, optionally substituted C1-C6 alkoxy, optionally substituted C1-C6 alkyl, —OH, —SH, —NH 2 , —N 3 , —CN, —NO 2 , —CHO, —COOH, —CONH 2 , —C(═NH)NH 2 , or —SO 3 H.

8. A compound selected from the group consisting of:

or a pharmaceutically acceptable salt thereof.

9. The compound, or pharmaceutically acceptable salt thereof, according to claim 2 , wherein the compound is a compound of Formula 15, and wherein R 1 is H; R 2 is H, R 4 is tertbutyl; and R 5 is CH 3 .

10. The compound, or pharmaceutically acceptable salt thereof, according to claim 2 , wherein the compound is a compound of Formula 15, and wherein Z 2 is NH.

11. The compound, or pharmaceutically acceptable salt thereof, according to claim 9 , wherein the compound is a compound of Formula 15, and wherein Z 2 is NH.

12. A pharmaceutical composition comprising the compound, or pharmaceutically acceptable salt thereof, according to claim 1 , and a pharmaceutically acceptable carrier or excipient.

13. A method of treating a cancer in a subject in need thereof, comprising administering to the subject in need thereof a therapeutically effective amount of the compound, or pharmaceutically acceptable salt thereof, of claim 1 .

14. The method according to claim 13 , wherein the cancer is a MUC1 positive or MUC1* positive cancer.

15. The method according to claim 13 , wherein the cancer is an NME7 AB or NME7-X1 positive cancer.

16. The method according to claim 13 , further comprising analyzing a cancerous sample from the subject and determining the cancer is a MUC1* positive, NME74 AB positive or NME7-X1 cancer.

17. A method of treating an inflammatory disease or condition comprising administering to a subject in need thereof a therapeutically effective amount of the compound, or pharmaceutically acceptable salt thereof, of claim 1 .

18. The method according to claim 17 , wherein the inflammatory disease or condition is rheumatoid arthritis, inflammatory bowel syndrome, Crohn's disease, osteoarthritis, asthma, dermatitis, psoriasis, cystic fibrosis, post transplantation late and chronic solid organ rejection, multiple sclerosis, systemic lupus erythematosus, Sjogren syndrome, Hashimoto thyroiditis, polymyositis, scleroderma, Addison disease, vitiligo, pernicious anemia, glomerulonephritis, pulmonary fibrosis, autoimmune diabetes, diabetic retinopathy, rhinitis, ischemia-reperfusion injury, post-angioplasty restenosis, chronic obstructive pulmonary diseases (COPD), Graves' disease, gastrointestinal allergy, conjunctivitis, atherosclerosis, coronary artery disease, angina, cancer metastasis, small artery disease, or mitochondrial disease.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 28, 2023
From: BAMDAD, CYNTHIA; MOE, SCOTT
To: MINERVA BIOTECHNOLOGIES CORPORATION
Reel/Frame 062890/0119 →
Continuity (4)
Continuation 16498640
Provisional Application 62607880 · Dec 19, 2017
Provisional Application 62478382 · Mar 29, 2017
Related Publication 20220242823A1 · Aug 4, 2022
References Cited (54)
US 5665719A · Bock et al. · 1997 [cited by applicant]
US 6960588B1 · Martin · 2005 [cited by applicant]
US 11931347B2 · Bamdad · 2024 [cited by examiner]
US 20090012077A1 · Dossetter · 2009 [cited by examiner]
US 20090047675A1 · Roberts et al. · 2009 [cited by applicant]
US 20150274671A1 · Pinto et al. · 2015 [cited by applicant]
US 20180263964A1 · Bamdad · 2018 [cited by examiner]
US 20210087143A1 · Bamdad et al. · 2021 [cited by applicant]
US 20210299109A1 · Bamdad · 2021 [cited by examiner]
JP H0687810A · 1994 [cited by applicant]
JP 2008521910A · 2008 [cited by applicant]
WO WO0014097A2 · 2000 [cited by applicant]
WO WO0146168A1 · 2001 [cited by applicant]
WO WO2009042815A1 · 2009 [cited by applicant]
WO WO2010032856A1 · 2010 [cited by applicant]
WO WO2011159960A2 · 2011 [cited by applicant]
WO WO2014014050A1 · 2014 [cited by applicant]
WO WO2015023694A2 · 2015 [cited by applicant]
WO WO2015107724A1 · 2015 [cited by applicant]
WO WO2015157322A2 · 2015 [cited by applicant]
WO WO2017053886A2 · 2017 [cited by applicant]
WO WO2018183654A1 · 2018 [cited by applicant]
WO WO2019126357A1 · 2019 [cited by applicant]
Audia et al. Pictet-Spengler-like Synthesis of Tetrahydro-P-carbolines under Hydrolytic Conditions. Direct Use of Azalactones as Phenylacetaldehyde Equivalents, J. Org. Chem. 61(22):7937-7939 (1996). [cited by applicant]
Belkina et al. BET protein function is required for inflammation: Brd2 genetic disruption and BET inhibitor JQ1 impair mouse macrophage inflammatory responses. J Immunol. 190(7):3670-8 (2013). [cited by applicant]
Cahn et al. IUPAC 1974 Recommendations for Section E, Fundamental Stereochemistry, Pure Appl. Chem. 45:13-30 (1976). [cited by applicant]
Carter et al. A Primitive Growth Factor, NME7AB , Is Sufficient to Induce Stable Naïve State Human Pluripotency; Reprogramming in This Novel Growth Factor Confers Superior Differentiation. Stem Cells 34(4):847-59 (2016). [cited by applicant]
Chemical Abstracts STN Registry Database, record for RN 1212062-80-0, Entered into STN on Mar. 21, 2010. (2010). [cited by applicant]
Chemical Abstracts STN Registry Database, record for RN 1212206-18-2, Entered into STN on Mar. 21, 2010. (2010). [cited by applicant]
Chemical Abstracts STN Registry Database, record for RN 1212244-17-1, Entered into STN on Mar. 21, 2010. (2010). [cited by applicant]
Chemical Abstracts STN Registry Database, record for RN 1212257-84-5, Entered into STN on Mar. 21, 2010. (2010). [cited by applicant]
Chemical Abstracts STN Registry Database, record for RN 1212425-09-6, Entered into STN on Mar. 21, 2010. (2010). [cited by applicant]
Chemical Abstracts STN Registry Database, record for RN 1214627-71-0, Entered into STN on Mar. 25, 2010. (2010). [cited by applicant]
Filippakopoulos et al. Selective inhibition of BET bromodomains. Nature 468:1067-1073 (2010). [cited by applicant]
Gafni et al. Derivation of novel human ground state naive pluripotent stem cells. Nature 504:282-286 (2013). [cited by applicant]
Hanna et al. Human embryonic stem cells with biological and epigenetic characteristics similar to those of mouse ESCs. PNAS USA 107(20):9222-9227 (2010). [cited by applicant]
Herbst et al. α-Acetaminocinnamic acid. Organic Syntheses 19:1 (1939). [cited by applicant]
Hikita et al. MUC1 Mediates the Growth of Human Pluripotent Stem Cells. PLoS One 3(10):1-13 (2008). [cited by applicant]
Horm et al. MUC1 drives c-Met-dependent migration and scattering. Mol Cancer Res. 10(12):1544-54 (2012). [cited by applicant]
Mani et al. The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells. Cell 133:704-715 (2008). [cited by applicant]
Meng et al. BET Inhibitor JQ1 Blocks Inflammation and Bone Destruction. J Dent Res. 93(7):657-662 (2014). [cited by applicant]
MENG et sl. Dexamethasone disrupts cytoskeleton organization and migration of T47D Human breast cancer cells by modulating the AKT/mTOR/RhoA pathway. Asian Pac J Cancer Prev 15(23):10245-50 (2014). [cited by applicant]
Nencini et al. Structure-activity relationship and properties optimization of a series of Quinazoline-2,4-diones as inhibitors of the canonical Wnt pathway. European Journal of Medicinal Chemistry 95:526-45 (2015). [cited by applicant]
Nichols et al. Naive and primed pluripotent states. Cell Stem Cell 4(6):487 (2009). [cited by applicant]
PCT/US2018/025107 International Search Report and Written Opinion dated Aug. 1, 2018. [cited by applicant]
Sachdeva. Drug targeting systems for cancer chemotherapy. Expert Opin Investig Drugs 7(11):1849-64 (Nov. 1998). [cited by applicant]
Silva et al., Promotion of reprogramming to ground state pluripotency by signal inhibition. PLoS Biol. 6(10):e253 (2008). [cited by applicant]
Smagghe et al. MUCI ligand, NM23-H1, is a novel growth factor that maintains human stem cells in a more naive state. PLoS One 8(3):E58601 (2013). [cited by applicant]
Tang et al. Assessment of Brd4 inhibition in idiopathic pulmonary fibrosis lung fibroblasts and in vivo models of lung fibrosis. Am J Pathol183(2):470-9 (2013). [cited by applicant]
Theunissen et al., Systematic identification of culture conditions for induction and maintenance of naive human pluripotency. Cell Stem Cell. 15(4):524-526 (2014). [cited by applicant]
U.S. Appl. No. 16/498,640 Office Action dated Apr. 29, 2021. [cited by applicant]
Ware et al. Derivation of naive human embryonic stem cells. PNAS USA 111:4484-4489 (2014). [cited by applicant]
Xu et al. MicroRNA-145 Regulates OCT4, SOX2, and KLF4 and Represses Pluripotency in Human Embryonic Stem Cells. Cell. 137(4):647-658 (2009). [cited by applicant]
Zheng et al. Synthesis and biological evaluation of novel tetrahydro-β-carboline derivatives as antitumor growth and metastasis agents through inhibiting the transforming growth factor-β signaling pathway. J Med Chem. 5… [cited by applicant]
Cited By (2)
US 12,491,259 US 12,630,512